- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.00 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x P8V: 2-[5-(cyclopropylmethyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]-3-{3-[(5-methylthiophen-2-yl)ethynyl]phenyl}-1H-pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid(Non-covalent)
P8V.2: 23 residues within 4Å:- Chain A: R.106, L.107, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.1, EDO.3
16 PLIP interactions:16 interactions with chain A- Hydrophobic interactions: A:R.106, A:L.109, A:V.110, A:N.138, A:P.139, A:I.142, A:A.238, A:Y.239
- Hydrogen bonds: A:N.138, A:D.141, A:D.141, A:I.142, A:E.192, A:T.248
- Salt bridges: A:R.169, A:H.193
P8V.8: 22 residues within 4Å:- Chain B: R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.7, EDO.9
16 PLIP interactions:16 interactions with chain B- Hydrophobic interactions: B:L.109, B:V.110, B:N.138, B:P.139, B:P.139, B:A.238, B:Y.239
- Hydrogen bonds: B:N.138, B:D.141, B:D.141, B:I.142, B:E.192, B:T.248
- Salt bridges: B:R.169, B:H.193
- pi-Cation interactions: B:R.106
P8V.14: 23 residues within 4Å:- Chain C: R.106, L.107, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.13, EDO.15
16 PLIP interactions:16 interactions with chain C- Hydrophobic interactions: C:R.106, C:L.109, C:V.110, C:N.138, C:P.139, C:I.142, C:A.238, C:Y.239
- Hydrogen bonds: C:N.138, C:D.141, C:D.141, C:I.142, C:E.192, C:T.248
- Salt bridges: C:R.169, C:H.193
P8V.20: 22 residues within 4Å:- Chain D: R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.19, EDO.21
16 PLIP interactions:16 interactions with chain D- Hydrophobic interactions: D:L.109, D:V.110, D:N.138, D:P.139, D:P.139, D:A.238, D:Y.239
- Hydrogen bonds: D:N.138, D:D.141, D:D.141, D:I.142, D:E.192, D:T.248
- Salt bridges: D:R.169, D:H.193
- pi-Cation interactions: D:R.106
- 16 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 4 residues within 4Å:- Chain A: R.106, Y.239, I.242
- Ligands: P8V.2
Ligand excluded by PLIPEDO.4: 3 residues within 4Å:- Chain A: E.176
- Chain B: P.75, K.76
Ligand excluded by PLIPEDO.5: 4 residues within 4Å:- Chain A: Q.233, E.240
- Chain B: K.59, M.63
Ligand excluded by PLIPEDO.6: 8 residues within 4Å:- Chain A: S.202, G.203, M.204, N.205, G.208, S.210
- Chain D: S.202, G.208
Ligand excluded by PLIPEDO.9: 3 residues within 4Å:- Chain B: Y.239, I.242
- Ligands: P8V.8
Ligand excluded by PLIPEDO.10: 3 residues within 4Å:- Chain B: L.173, E.176, R.177
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain B: V.200, W.201, S.202, T.309, E.312
Ligand excluded by PLIPEDO.12: 5 residues within 4Å:- Chain B: W.148, G.152, F.153, P.154, K.155
Ligand excluded by PLIPEDO.15: 4 residues within 4Å:- Chain C: R.106, Y.239, I.242
- Ligands: P8V.14
Ligand excluded by PLIPEDO.16: 3 residues within 4Å:- Chain C: E.176
- Chain D: P.75, K.76
Ligand excluded by PLIPEDO.17: 4 residues within 4Å:- Chain C: Q.233, E.240
- Chain D: K.59, M.63
Ligand excluded by PLIPEDO.18: 8 residues within 4Å:- Chain B: S.202, G.208
- Chain C: S.202, G.203, M.204, N.205, G.208, S.210
Ligand excluded by PLIPEDO.21: 3 residues within 4Å:- Chain D: Y.239, I.242
- Ligands: P8V.20
Ligand excluded by PLIPEDO.22: 3 residues within 4Å:- Chain D: L.173, E.176, R.177
Ligand excluded by PLIPEDO.23: 5 residues within 4Å:- Chain D: V.200, W.201, S.202, T.309, E.312
Ligand excluded by PLIPEDO.24: 5 residues within 4Å:- Chain D: W.148, G.152, F.153, P.154, K.155
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rai, G. et al., Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. J.Med.Chem. (2020)
- Release Date
- 2020-09-23
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
CC
AD
C
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.00 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x P8V: 2-[5-(cyclopropylmethyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]-3-{3-[(5-methylthiophen-2-yl)ethynyl]phenyl}-1H-pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid(Non-covalent)
- 16 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rai, G. et al., Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. J.Med.Chem. (2020)
- Release Date
- 2020-09-23
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
CC
AD
C